NeOnc Technologies Holdings (NASDAQ: NTHI) disclosed that its chief executive, president, director, and 10% owner, Amir F. Heshmatpour, bought 30,000 shares of the company's common stock on November 13, 2026. The total value of the acquisition was $150,501, according to the filing.
The shares changed hands at a weighted average price of $5.0167. Individual purchases within the transaction were executed at prices between $4.89 and $5.19 per share, a range that brackets the stock's recent trading level.
The purchase arrives during a sharp move in NTHI shares, which have surged 40.69% over the past week. The stock is currently trading at $4.91, and the company carries a market capitalization of $134.69 million. An analysis of the stock describes it as overvalued relative to its Fair Value, while the company's financial health is rated as FAIR.
After the transaction, Heshmatpour directly holds 3,353,000 shares of common stock. That figure includes 275,000 shares held by certain members of his immediate family. Heshmatpour disclaims beneficial ownership of those shares except to the extent of his pecuniary interest, if any.
His ownership also extends through several indirect holdings. He holds indirect beneficial ownership of 256,120 shares through his proportionate interest in HCWG LLC. In addition, he indirectly owns 550,000 shares held by KIG LLC, where his spouse is the sole member; he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest, if any. Furthermore, he indirectly holds 3,714,020 shares through AFH Holdings & Advisory, LLC, where he serves as the sole member and manager.
In other recent developments, Roth/MKM initiated coverage on NeOnc Technologies with a buy rating and a price target of $20.00. The firm's analysis relied on a discounted cash flow approach, applying a 20% discount rate and a 5x multiple of projected $667 million in operating income by 2033.
Roth/MKM expects NeOnc Technologies' products NEO100 and NEO212 to launch in 2029 and 2030, respectively. These products are intended for the treatment of recurrent grade 4 astrocytoma, as well as recurrent glioblastoma and brain metastases. The initiation of pivotal trials for these products could potentially begin by the end of 2026.
Taken together, the insider purchase and the analyst initiation highlight recent activity around NeOnc Technologies' strategic plans and projected timelines for its product pipeline. The stock's weekly gain and the valuation assessment provide additional context for how the market has recently priced the shares.